Thrasos raises $35 million for kidney drug development

Guest Contributor
November 9, 2012

Privately held Thrasos Therapeutics has raised $35 million in financing from a consortium of investors to take THR-184 — its lead compound for the treatment of acute kidney injury — through to Phase II clinical proof of concept. Investors in the Montreal-based firm are: SR One, GSK Life Sciences Innovation Fund, SW Co, Advanced Technology Ventures, Fonds de solidarité FTQ, Lumira Capital, MP Healthcare Venture Management and Pappas Ventures....

Other News

Events For Leaders in
Science, Tech, Innovation, and Policy

Discuss and learn from those in the know at our virtual and in-person events.

See Upcoming Events

You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in


By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.